DIABETES THERAPY TO IMPROVE BMI AND PULMONARY FUNCTION IN CYSTIC FIBROSIS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 (1)与对照组相比，接受胰岛素或瑞格列奈治疗的参与者会增加他们的BMI。(2)胰岛素在增加BMI方面比瑞格列奈更有效。(3)BMI的增加将主要是由于肌肉质量的增加。(4)体重指数的增加将在饮食中大量营养素或卡路里组成没有明显变化的情况下实现。(5)胰岛素或瑞格列奈治疗将防止肺功能下降，与对照组和他们自己前一年测量的基线相比。这将与NIH临床评分的改善有关，并将与体重增加和大腿肌肉体积的增加直接相关。(6)服用胰岛素或瑞格列奈的受试者会改善握力，这与体重增加和大腿肌肉体积增加有直接关系。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (1) Participants receiving either insulin or repaglinide will increase their BMI compared to control participants. (2) Insulin will be more effective than repaglinide at increasing BMI. (3) The increase in BMI will be primarily due to increased muscle mass. (4) The increase in BMI will be accomplished without significant changes in dietary macronutrient or calorie composition. (5) Insulin or repaglinide therapy will prevent pulmonary function decline compared to both control subjects and to their own baseline as measured the previous year. This will be associated with improvement in NIH clinical score and will be directly related to weight gain and increase in thigh muscle volume. (6) Participants receiving insulin or repaglinide will improve hand grip strength, and this will be directly related to weight gain and increase in thigh muscle volume.